ProKidney: Hold Rating Amid Encouraging Developments and Cautious Outlook

Morgan Stanley analyst Judah Frommer maintained a Hold rating on ProKidney today and set a price target of $3.00.

Judah Frommer has given his Hold rating due to a combination of factors related to ProKidney’s recent developments and financial outlook. The company has made notable progress in its Phase 3 PROACT 1 study, with more than half of the necessary patients enrolled for the accelerated approval analysis. This progress is encouraging, especially following the supportive topline data from the REGEN-007 study and the FDA’s agreement to use eGFR as a surrogate endpoint.
Despite these positive developments, Frommer maintains a cautious stance, as the full results of the REGEN-007 study are still pending and expected to be presented at ASN Kidney Week. Additionally, while the company has a cash runway extending into mid-2027, the current stock price and market capitalization suggest limited upside potential in the near term. As a result, the $3 price target remains unchanged, reflecting a balanced view of the risks and opportunities associated with ProKidney’s ongoing clinical and regulatory activities.